S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Forecast, Price & News

$3.86
+0.36 (+10.29%)
(As of 06/8/2023 ET)
Compare
Today's Range
$3.60
$4.00
50-Day Range
$0.79
$3.50
52-Week Range
$0.61
$4.00
Volume
1.32 million shs
Average Volume
542,399 shs
Market Capitalization
$179.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.83

Corvus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
51.1% Upside
$5.83 Price Target
Short Interest
Healthy
1.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$24,500 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

335th out of 981 stocks

Pharmaceutical Preparations Industry

153rd out of 475 stocks


CRVS stock logo

About Corvus Pharmaceuticals (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Stock News Headlines

“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Our #1 Laser Stock for May
The Pentagon calls laser weapons "the future." This small cap just won a $1.65 billion contract to make them. See why this stock could soar 2,476% >>>
See More Headlines

CRVS Price History

CRVS Company Calendar

Last Earnings
3/28/2023
Today
6/08/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRVS
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.83
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.50
Forecasted Upside/Downside
+54.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-41,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.21 per share

Miscellaneous

Free Float
31,993,000
Market Cap
$176.03 million
Optionable
Not Optionable
Beta
1.07

Key Executives

  • Dr. Richard A. Miller M.D. (Age 72)
    Co-Founder, Pres, CEO & Chairman
    Comp: $306k
  • Dr. Peter A. Thompson FACP (Age 63)
    M.D., Co-Founder & Independent Director
    Comp: $47k
  • Mr. Leiv Lea (Age 69)
    Chief Financial Officer
    Comp: $388.73k
  • Dr. William Benton Jones Ph.D. (Age 57)
    Sr. VP of Pharmaceutical Devel.
    Comp: $346.42k
  • Dr. James T. Rosenbaum M.D.
    Sr. VP of Research













CRVS Stock - Frequently Asked Questions

Should I buy or sell Corvus Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRVS shares.
View CRVS analyst ratings
or view top-rated stocks.

What is Corvus Pharmaceuticals' stock price forecast for 2023?

3 brokerages have issued 12-month price objectives for Corvus Pharmaceuticals' stock. Their CRVS share price forecasts range from $3.50 to $10.00. On average, they anticipate the company's stock price to reach $5.83 in the next year. This suggests a possible upside of 54.3% from the stock's current price.
View analysts price targets for CRVS
or view top-rated stocks among Wall Street analysts.

How have CRVS shares performed in 2023?

Corvus Pharmaceuticals' stock was trading at $0.85 at the beginning of the year. Since then, CRVS shares have increased by 344.7% and is now trading at $3.78.
View the best growth stocks for 2023 here
.

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 455,500 shares, an increase of 209.2% from the April 30th total of 147,300 shares. Based on an average daily trading volume, of 713,100 shares, the short-interest ratio is currently 0.6 days. Currently, 1.3% of the company's stock are short sold.
View Corvus Pharmaceuticals' Short Interest
.

When is Corvus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CRVS earnings forecast
.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) posted its quarterly earnings results on Tuesday, March, 28th. The company reported ($0.21) earnings per share (EPS) for the quarter.

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include CHI Advisors LLC (5.02%), Renaissance Technologies LLC (1.09%), Two Sigma Investments LP (0.44%), Two Sigma Advisers LP (0.40%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Ecor1 Capital, Llc, Holdings A/S Novo, Leiv Lea, Linda Grais, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones.
View institutional ownership trends
.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $3.78.

How much money does Corvus Pharmaceuticals make?

Corvus Pharmaceuticals (NASDAQ:CRVS) has a market capitalization of $176.03 million. The company earns $-41,310,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The official website for the company is www.corvuspharma.com. The company can be reached via phone at (650) 900-4520 or via email at llea@corvuspharma.com.

This page (NASDAQ:CRVS) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -